The product is Sandimmune oral solution (cyclosporine), which is approved for the prophylaxis of organ rejection in kidney, liver and heart transplants. The drug is also indicated for treating chronic rejection of transplants.
No adverse events have been reported. The crystallization could cause doses to be too strong or weak. The FDA said “there is a reasonable probability” under-dosing can lead to graft rejection and graft loss in transplant patients, and over-dosing could “manifest itself as cyclosporine toxicity in the long term if over exposure continues.”
Novartis is contacting healthcare providers who have prescribed the drug and is asking distributors to return their supply.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
